ADA

Depressive symptoms and history of suicide attempts linked with higher HbA1c

Users spent more time in target glucose range than those on sensor augmented pump therapy

Steady decreases in the prevalence of patients with eye problems may be over

But clinical trial currently under FDA hold as dosing is discussed

Subanalysis of SURPASS-4 trial compared the GLP-1/GIP agonist against insulin glargine

Mixed results in seven-study scoping review

Safety profile consistent with that reported in adults

SURMOUNT-1 trial tested GIP/GLP-1 receptor agonist in people without diabetes

Study looked at people with obesity who underwent two most popular procedures

Disparities differed by sex and age group

Noteworthy research from the American Diabetes Association virtual meeting

People with highest risk genetics more than 15 times more likely to have T2D

Head-to-head comparison could help individualize treatment

Providers should be screening patients on how COVID is affecting them, says researcher